BFM
NMRA icon

Boothbay Fund Management’s Neumora Therapeutics NMRA Stock Holding History

Boothbay Fund Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-101,000
Closed -$1.07M – 1656
2024
Q4 		$1.07M Sell
101,000
-16,000
-14% -$192K 0.03% 614
2024
Q3 		$1.55M Buy
+117,000
New +$1.36M 0.04% 613

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

Boothbay Fund Management's NMRA Position: Q1 2026 in Review

Boothbay Fund Management held its Neumora Therapeutics (NMRA) position steady in Q1 2026 at 335,267 shares worth $654K. The position accounts for 0.01% of the portfolio, ranked #1187.

Boothbay Fund Management first reported a position in NMRA in Q4 2025 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • Boothbay Fund Management held 335,267 shares of Neumora Therapeutics worth $654K as of Q1 2026.
  • Boothbay Fund Management left its Neumora Therapeutics share count unchanged in Q1 2026.
  • Neumora Therapeutics made up 0.01% of Boothbay Fund Management's portfolio in Q1 2026, its #1187 holding.
  • Boothbay Fund Management first reported a position in Neumora Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.